GENITOURINARY & SEXUAL HEALTH

Understanding Vulvovaginal Changes After Menopause

✦ CLINICAL PEARL

Many urinary and vaginal symptoms are common after menopause but should never be dismissed simply as “normal aging.” Evidence-based treatments are available.

Overview

Vulvovaginal changes after menopause are common. Declining estrogen can affect the vulva, vagina, urethra, bladder, and pelvic floor. These changes may contribute to vaginal dryness, irritation, painful intercourse, urinary symptoms, and recurrent urinary tract infections. Understanding what may be contributing is often the first step toward a useful conversation with your healthcare professional.

Understanding the anatomy

The vulva is the external genital area. The vagina is the internal canal that connects the vulva to the uterus. The urethra is the short tube that carries urine from the bladder out of the body. The pelvic floor is a group of muscles that support the bladder, uterus, and rectum.

How estrogen normally supports these tissues

  • Blood flow to vulvar and vaginal tissue
  • Natural lubrication
  • Collagen and tissue elasticity
  • The vaginal microbiome
  • Glycogen in vaginal cells
  • A more acidic vaginal pH

What changes during menopause?

  • Estrogen declines
  • Vaginal and vulvar tissue may become thinner
  • Tissue may lose elasticity
  • Natural lubrication may decrease
  • The vaginal microbiome may shift
  • Vaginal pH may rise (become less acidic)
  • Blood flow to the area may decrease
  • Collagen may decrease

Common symptoms

  • Dryness
  • Burning
  • Itching
  • Irritation
  • Painful intercourse
  • Decreased lubrication
  • Urinary urgency
  • Urinary frequency
  • Recurrent UTIs
  • Painful urination
  • Urinary leakage
  • Reduced sexual satisfaction

Understanding GSM

Genitourinary Syndrome of Menopause (GSM) is a term that describes the collection of vulvar, vaginal, and urinary symptoms that can occur when estrogen declines. Common features include dryness, irritation, painful intercourse, urinary urgency or frequency, and recurrent urinary tract infections. GSM is often underrecognized because many women assume symptoms are simply a normal part of aging. Symptoms can meaningfully affect quality of life, sleep, intimacy, and daily comfort. A healthcare professional can help sort out what may be contributing and which options are appropriate for you.

Treatment options at a glance

  • Lubricants

    Prescription required
    No
    Hormonal vs non-hormonal
    Non-hormonal
    May help dryness
    Yes, during use
    May help painful sex
    May help friction-related discomfort
    May help urinary symptoms
    Not typically
    May help recurrent UTIs
    Not typically

  • Vaginal moisturizers

    Prescription required
    No
    Hormonal vs non-hormonal
    Non-hormonal
    May help dryness
    May help with regular use
    May help painful sex
    May help
    May help urinary symptoms
    Not typically
    May help recurrent UTIs
    Not typically

  • Low-dose vaginal estrogen

    Prescription required
    Yes
    Hormonal vs non-hormonal
    Hormonal (local)
    May help dryness
    May help
    May help painful sex
    May help
    May help urinary symptoms
    May help
    May help recurrent UTIs
    May help

  • Vaginal DHEA (prasterone)

    Prescription required
    Yes
    Hormonal vs non-hormonal
    Hormonal (local)
    May help dryness
    May help
    May help painful sex
    May help
    May help urinary symptoms
    Individualized
    May help recurrent UTIs
    Individualized

  • Ospemifene

    Prescription required
    Yes
    Hormonal vs non-hormonal
    Non-estrogen oral (SERM)
    May help dryness
    May help
    May help painful sex
    May help
    May help urinary symptoms
    Individualized
    May help recurrent UTIs
    Individualized

  • Pelvic floor physical therapy

    Prescription required
    Referral typically needed
    Hormonal vs non-hormonal
    Non-hormonal
    May help dryness
    Not directly
    May help painful sex
    May help pain related to pelvic floor
    May help urinary symptoms
    May help selected urinary symptoms
    May help recurrent UTIs
    Not directly

  • Systemic menopausal hormone therapy (when appropriate)

    Prescription required
    Yes
    Hormonal vs non-hormonal
    Hormonal (systemic)
    May help dryness
    May help
    May help painful sex
    May help
    May help urinary symptoms
    May help
    May help recurrent UTIs
    Not first-line for this indication

How this section is organized

Two different concerns are often discussed together but are evaluated differently. **Part 1 — GSM** covers tissue-related symptoms: dryness, burning, urinary symptoms, and painful sex. **Part 2 — Sexual desire (HSDD)** covers persistent low desire with personal distress. The summaries below are educational overviews of treatment categories, not recommendations for any individual.

Part 1 — GSM: vaginal moisturizers and lubricants

What they are: Non-prescription, non-hormonal products. Lubricants (water-, silicone-, or oil-based) are applied at the time of sexual activity to reduce friction. Vaginal moisturizers are used on a regular schedule — often several times a week — to help the tissue hold moisture over time. Intended for: Dryness, irritation, and friction-related discomfort, including painful sex. Common benefits: Widely available, low cost, no prescription, and often a reasonable first step for mild symptoms. They can be used alongside prescription treatments. Precautions at a high level: They relieve symptoms but do not change the underlying tissue. Some products contain fragrances, warming agents, glycerin, or preservatives that can irritate sensitive tissue; oil-based products may weaken latex condoms. Persistent or worsening symptoms deserve evaluation rather than continued self-treatment.

Vaginal estrogen — how it works

Low-dose vaginal estrogen delivers estrogen directly to vulvovaginal and urinary tissue. Formulations include creams, tablets, softgel inserts, and a vaginal ring. Blood levels of estrogen remain low with standard low-dose vaginal preparations. It is commonly considered when non-prescription options are not sufficient, and treatment choice is made through shared decision-making with your clinician.

Vaginal estrogen — evidence and context

Low-dose vaginal estrogen has one of the strongest evidence bases for moderate-to-severe GSM symptoms when nonprescription therapies are insufficient. Current evidence has not demonstrated increased risks of breast cancer, cardiovascular disease, stroke, or venous thromboembolism with low-dose vaginal estrogen in the general population, although long-term randomized safety data remain limited. For women with a history of estrogen-dependent breast cancer, particularly those taking aromatase inhibitors, treatment decisions should involve shared decision-making with the patient and appropriate oncology and gynecology clinicians. A progestogen is generally not recommended with standard low-dose vaginal estrogen used for GSM. Any postmenopausal bleeding should be evaluated. In 2025–2026, the FDA approved updated labeling for several menopausal hormone therapy products, including a topical vaginal estrogen product, removing certain boxed warning language while maintaining product-specific precautions.

Vaginal DHEA (prasterone, Intrarosa)

What it is: A vaginal insert containing prasterone, a form of DHEA that vaginal cells can convert locally into small amounts of estrogen and androgen. It is FDA-approved for moderate-to-severe painful intercourse (dyspareunia) due to menopause. It is used nightly. Intended for: Painful sex related to GSM; studies have also reported improvements in vaginal dryness and tissue measures such as vaginal pH and cell maturation. Precautions at a high level: It is a hormonal product, so undiagnosed abnormal genital bleeding is a contraindication, and use in women with a history of hormone-sensitive cancer is an individualized decision made with oncology input. Vaginal discharge and application-site irritation are among the more commonly reported effects. Long-term and cancer-survivor safety data remain limited.

Oral ospemifene (Osphena)

What it is: A daily oral non-estrogen medication in the selective estrogen receptor modulator (SERM) class. It acts like estrogen on vaginal tissue while acting differently in other tissues. It is FDA-approved for moderate-to-severe dyspareunia and for moderate-to-severe vaginal dryness due to menopause. Intended for: Women with GSM who prefer or need an oral option rather than a vaginal product. Trials have shown improvement in vaginal cell maturation, pH, dryness, and painful sex. Precautions at a high level: Because it is systemically absorbed, labeling includes warnings related to endometrial effects and cardiovascular and thromboembolic events; it is generally avoided in women with a history of blood clots, stroke, undiagnosed vaginal bleeding, or estrogen-dependent cancer, and it is not used during pregnancy. Hot flashes are a commonly reported side effect. Suitability depends on personal medical history and requires a clinician evaluation.

Recurrent UTIs

After menopause, changes in the vaginal microbiome, tissue thinning, and altered vaginal pH may contribute to a higher risk of recurrent urinary tract infections. Low-dose vaginal estrogen has been shown to reduce recurrent urinary tract infections in appropriately selected postmenopausal women and is recommended in multiple professional guidelines. Reducing recurrent UTIs may plausibly reduce opportunities for serious complications such as kidney infection or urosepsis; however, clinical trials have not directly demonstrated prevention of pyelonephritis, urosepsis, or death.

Part 2 — Sexual health and desire after menopause

Sexual well-being after menopause involves desire, arousal, lubrication, orgasm, body image, sleep, mood, medications, relationships, and pelvic floor function. Vaginal dryness or discomfort can affect any of these, and treating tissue symptoms sometimes resolves concerns that were initially described as low desire. Low desire on its own is common and is not automatically a medical problem.

Hypoactive sexual desire disorder (HSDD)

HSDD describes persistently low or absent sexual desire that causes personal distress and is not better explained by another medical condition, medication effect, substance use, or significant relationship difficulty. It is a clinical evaluation, not a lab result — there is no blood test that diagnoses it. Because distress and context are part of the definition, assessment usually explores biological, psychological, relational, and cultural contributors together (a biopsychosocial approach). Counseling, sex therapy, addressing sleep, mood, pain, and reviewing medications that can lower desire (such as some antidepressants) are often part of the conversation before or alongside any medication.

Medication categories studied for HSDD

  • Relationship and biopsychosocial care — Sex therapy, cognitive behavioral approaches, couples counseling, mindfulness-based programs, and treating contributing factors such as pain, sleep disruption, depression, and medication side effects. These are frequently first-line and can be used alongside other options.
  • Transdermal testosterone — off-label in the United States — A global consensus position supports a trial of testosterone, in doses producing premenopausal physiologic blood levels, only for postmenopausal women with HSDD after evaluation. There is currently no FDA-approved testosterone product for women in the United States, so any use for HSDD is off-label and should be managed by an appropriately qualified clinician. Evidence does not support testosterone for fatigue, mood, bone, or cognition in women. Precautions include acne, unwanted hair growth, and — with excessive dosing — voice deepening or clitoral enlargement, which may not be reversible. Compounded pellets and injections are not recommended because they can produce supraphysiologic levels. Blood-level monitoring is advised.
  • Flibanserin (Addyi) — A daily oral non-hormonal medication acting on serotonin, dopamine, and norepinephrine pathways. FDA-approved for acquired, generalized HSDD in premenopausal women; use in postmenopausal women is off-label. Average improvements in trials were modest. Major precautions: hypotension and syncope, an interaction with alcohol, contraindication with strong CYP3A4 inhibitors (including some antifungals and antibiotics) and with hepatic impairment. It is taken at bedtime, and effects build over weeks.
  • Bremelanotide (Vyleesi) — An as-needed subcutaneous injection given about 45 minutes before anticipated sexual activity, acting on melanocortin receptors. FDA-approved for acquired, generalized HSDD in premenopausal women; use in postmenopausal women is off-label. Limitations: nausea is common and can be significant, along with flushing, headache, and injection-site reactions; transient blood pressure increases mean it is avoided in uncontrolled hypertension or known cardiovascular disease; darkening of the skin or gums can occur, and use is limited to no more than one dose per day and eight per month.

Why treatment selection must be individualized

  • Every option above has specific contraindications tied to personal medical history — clots, stroke, liver disease, undiagnosed bleeding, hormone-sensitive cancer, or blood pressure and alcohol considerations.
  • Two women with identical symptoms may be appropriate for entirely different approaches, or for none of them.
  • Several medications listed are FDA-approved only for premenopausal women, and testosterone has no FDA-approved female product in the United States.
  • Symptoms such as new pain, bleeding, a lump or lesion, fever with urinary symptoms, or symptoms that do not respond to treatment need evaluation rather than a medication change.

This page is educational information, not medical advice, and it is not a substitute for individualized evaluation, diagnosis, or treatment by a qualified healthcare professional. No treatment described here is recommended for any specific person.

Pelvic floor

The pelvic floor muscles support the bladder, uterus, and rectum. Menopause-related tissue changes and other life events can affect pelvic floor function. Pelvic floor physical therapy — often with a trained pelvic floor physical therapist — and pelvic floor muscle exercises may help selected symptoms such as painful intercourse related to pelvic floor tension, urinary urgency, or leakage. A clinician can help determine whether a referral is appropriate.

More myths worth revisiting

  • Lubricants and moisturizers are the same — Lubricants are used at the time of activity to reduce friction. Vaginal moisturizers are used on a regular schedule to support tissue hydration over time. They serve different purposes and can be used together.
  • Everyone needs vaginal estrogen — Not everyone with vulvovaginal symptoms needs prescription treatment. Non-prescription approaches are appropriate for many women, and decisions are individualized with a clinician.
  • UTIs after menopause are inevitable — Recurrent UTIs are more common after menopause but are not simply an unavoidable part of aging. Evaluation and evidence-based options exist.
  • Low libido is only hormonal — Desire and arousal are influenced by many factors including tissue comfort, sleep, mood, medications, relationships, and life circumstances — not hormones alone.

Myth vs. Fact

Myth

Painful sex is just part of aging.

Fact

Painful intercourse after menopause is common but is not something you have to accept. It often has treatable causes — including vaginal dryness, GSM, or pelvic floor factors — and deserves a thoughtful evaluation.

Questions to discuss with your clinician

  • Could my urinary or vaginal symptoms be related to GSM?
  • Are my recurrent UTIs related to menopause?
  • Would a non-prescription option (moisturizer or lubricant) be a reasonable first step?
  • Am I a candidate for low-dose vaginal estrogen, vaginal DHEA, or ospemifene?
  • Are there considerations because of my personal or family medical history?
  • Could pelvic floor physical therapy be helpful for me?
  • What symptoms should prompt evaluation for something other than menopause?
  • How will we know whether treatment is helping?

✓ EVIDENCE-BASED OVERVIEW · INDIVIDUAL EVALUATION MATTERS

Vulvovaginal changes after menopause are common and may contribute to vaginal dryness, irritation, painful intercourse, urinary symptoms, and recurrent urinary tract infections. Evidence-based options exist. Treatment is individualized in partnership with a qualified healthcare professional.

Learn next

Frequently asked questions

  • Why does menopause affect the bladder?

    Estrogen supports tissue in the urethra, bladder, and surrounding pelvic area. When estrogen declines, these tissues may change, contributing to urinary urgency, frequency, discomfort, or a higher risk of recurrent UTIs.

  • What is GSM?

    Genitourinary Syndrome of Menopause is a term that groups vulvar, vaginal, and urinary symptoms related to estrogen decline — including dryness, irritation, painful intercourse, urinary urgency or frequency, and recurrent UTIs.

  • Can menopause cause recurrent UTIs?

    Menopause-related changes can contribute to recurrent urinary tract infections. Low-dose vaginal estrogen has been shown to reduce recurrent UTIs in appropriately selected postmenopausal women and is recommended in multiple professional guidelines.

  • What is the difference between lubricants and moisturizers?

    Lubricants are used at the time of activity to reduce friction. Vaginal moisturizers are used on a regular schedule to support tissue hydration over time. They serve different purposes and can be used together.

  • What is the difference between vaginal estrogen, vaginal DHEA, and ospemifene?

    All three are prescription options for moderate-to-severe GSM. Low-dose vaginal estrogen is applied locally as a cream, tablet, insert, or ring. Vaginal DHEA (prasterone) is a nightly insert converted locally by vaginal cells and is FDA-approved for painful sex due to menopause. Ospemifene is a daily oral SERM approved for painful sex and vaginal dryness. They differ in route, evidence base, and precautions, so the choice is made with a clinician based on personal history.

  • Is testosterone approved for low desire in women?

    No FDA-approved testosterone product exists for women in the United States, so any use for HSDD is off-label. International consensus supports a trial only for postmenopausal women with HSDD after evaluation, at doses producing premenopausal physiologic levels, with monitoring by an appropriately qualified clinician.

  • How do Addyi and Vyleesi differ?

    Flibanserin (Addyi) is a daily bedtime pill with alcohol, blood-pressure, liver, and drug-interaction precautions. Bremelanotide (Vyleesi) is an as-needed injection used before anticipated activity, commonly causing nausea and limited to one dose per day and eight per month. Both are FDA-approved for acquired, generalized HSDD in premenopausal women; postmenopausal use is off-label.

  • When should I seek medical evaluation?

    Consider a visit for symptoms that are new, worsening, bothersome, or interfering with sleep, intimacy, or daily comfort. Any postmenopausal bleeding, severe pain, fever with urinary symptoms, or symptoms concerning for a serious infection should be evaluated promptly.

Future Membership Tools

Her Hormone Map Membership is being designed to help women organize symptoms, track patterns over time, and prepare more efficiently for healthcare visits.

Future membership concepts include:

  • Interactive Anatomy Explorer (educational)
  • Personalized symptom reports
  • AI-generated pattern summaries
  • Progress tracking over time
  • Appointment preparation summaries
Explore Membership

These tools will support — not replace — professional evaluation, diagnosis, or treatment. They are described as future benefits and are not represented as currently active.